Jacobs Levy Equity Management’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-666,574
| Closed | -$850K | – | 1173 |
|
|
2024
Q4 | $850K | Buy |
666,574
+491,595
| +281% | +$627K | ﹤0.01% | 737 |
|
|
2024
Q3 | $362K | Buy |
174,979
+157,218
| +885% | +$325K | ﹤0.01% | 866 |
|
|
2024
Q2 | $67.7K | Buy |
+17,761
| New | +$67.7K | ﹤0.01% | 937 |
|
|
2024
Q1 | – | Sell |
-131,307
| Closed | -$561K | – | 1030 |
|
|
2023
Q4 | $561K | Sell |
131,307
-12,650
| -9% | -$54K | ﹤0.01% | 813 |
|
|
2023
Q3 | $445K | Buy |
143,957
+27,470
| +24% | +$84.9K | ﹤0.01% | 827 |
|
|
2023
Q2 | $524K | Buy |
116,487
+31,820
| +38% | +$143K | ﹤0.01% | 817 |
|
|
2023
Q1 | $483K | Buy |
+84,667
| New | +$483K | ﹤0.01% | 808 |
|
|
2022
Q1 | – | Sell |
-130,280
| Closed | -$1.62M | – | 1070 |
|
|
2021
Q4 | $1.62M | Buy |
+130,280
| New | +$1.62M | 0.01% | 661 |
|